ASCO 2020：11项中国研究者入选口头报告，17项Poster报告

所致亚太地区从新冠疫情不良影响，月初于5同年29日~6同年2日在纽约举行的美国流行病学协亦会（ASCO）年亦会今年将首次以线上形式筹办，这是目前最大规模的线上盛亦会。以前，全体亦会议的概要作文出炉，合共103个sessions，里国分别为11项学术研究入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

芳基替尼或卡马替尼加卡培他鹿岛主要用途HER2+结核乳腺乳癌（PHOEBE）：一项III期随机次测试。

三场：结核乳腺乳癌

著者：里国医学科学院疗养院徐兵河博士、马飞博士，山东大学附属疗养院胡夕春博士等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三特征性乳腺乳癌标准放射治疗后卡培他鹿岛维系鼓点疗程的III期次测试（SYSUCC-001）。

三场：乳腺乳癌—暂时性/范围/基本功能放射治疗

著者：山东大学预防为里心王为树森博士等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用结核神经的表型特征来预报神经脊液里循环DNA探测的概率: 从新应用软件对抗据闻劲敌

三场：从新应用软件解决据闻问题

著者：李美芹 李昔等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为早期肾巨噬细胞乳癌的一线放射治疗：一项免费页面、随机、多为里心II/III期次测试。

三场：肠道乳癌—消化道输尿管、胰腺和肾胆

著者：西安交通大学亚东疗养院毕锋博士、里国人民解放军八一疗养院秦叔逵博士等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国早期肾乳癌患儿阿帕替尼主干线放射治疗：一项随机、安慰剂印证、测试者III期学术研究

三场：肠道乳癌—消化道输尿管、胰腺和肾胆

著者：里国人民解放军八一疗养院秦叔逵博士、西安交通大学亚东疗养院李秋博士等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期入院性卵巢乳癌二次巨噬细胞减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

简介：医学肺炎

著者：山东大学附属里山疗养院臧荣余博士等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性子宫切除术后基本功能放射治疗里的序贯放疗程对比单独超声或互联放疗程（STARS学术研究）：一项随机、印证、免费页面的III期次测试。

全体亦会议：医学肺炎

著者：山东大学预防为里心黄鹤博士、刘继红博士等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比疗程主要用途可切除的EGFR等位基因的N1-N2期NSCLC-随机III期流行病学次测试的再度各个方面肉食动物系统性。

简介：肺炎—非小巨噬细胞暂时性-范围/小巨噬细胞/其他面部

著者：广州市人民疗养院吴一龙博士等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因寡移出非小巨噬细胞肺炎患儿一线半胱氨酸磷酸化酶抑制剂联合行动或不联合行动致力前线暂时性超声：III期免费页面流行病学随机次测试（SINDAS）的后半期结果（NCT02893332）。

简介：肺炎-非小巨噬细胞移出

著者：贵州省人民疗养院曾铭博士等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性失踪-1（PD-1）的人源化IgG4单克隆抗体联合行动阿昔替尼主要用途结核上皮细胞黑色素瘤患儿的Ib期学术研究的总肉食动物期和微生物标志物系统性。

简介：黑色素瘤/皮肤乳癌

著者：北京大学疗养院郭军、盛锡楠博士等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容性和结果：统一标准CAR-T巨噬细胞首次生理次测试放射治疗入院/难治性T巨噬细胞急性淋巴巨噬细胞癌症（r/r T-ALL）的相容性和。全体亦会议：开发从新里的放射治疗电子技术-免疫放射治疗。著者：王为恰巧等概要：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利唑在早期输尿管鳞状巨噬细胞乳癌患儿里的运用：一项随机的免费页面II期次测试（ORIENT-2）。全体亦会议：肠道乳癌-消化道输尿管乳癌、癌症和肾胆道乳癌著者：徐建明博士等概要：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D选择性CAR-T巨噬细胞对髓母巨噬细胞瘤的根除性放射治疗全体亦会议：里枢神经系统著者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东概要：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复缺点患儿里的运用全体亦会议：开发从新里的放射治疗学-免疫放射治疗著者：沈琳博士等概要：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART放射治疗入院/难治性ACUTE淋巴巨噬细胞癌症/淋巴瘤的首例生理流行病学次测试全体亦会议: 开发从新性放射治疗学-免疫放射治疗著者简介：张明志，陈东等概要：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合行动运主要用途早期实质瘤患儿的Ib期学术研究全体亦会议：发展性放射治疗学便是小分子载体药物和微分子生物学著者：龚继芳，沈琳博士等概要：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动萘和nedaplatin放射治疗入院性或结核输尿管鳞状巨噬细胞乳癌（ESCC）患儿的II期学术研究。全体亦会议：肠道乳癌-消化道输尿管、胰腺和肾胆道乳癌的学术研究著者：王为志爆冷，李玉红，王为德申，王为凤华，任超，谭琼 王为志爆冷、李玉红、王为德深、王为凤华、任超、谭琼概要：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体亦会议：肠道乳癌-消化道输尿管乳癌、癌症和肾胆管乳癌的主干线放射治疗著者：宋艳等概要：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿外体环状RNA分类器主要用途初始活检时探测高等级乳癌的尿外体环状RNA分类器：一项多为里心的回顾性学术研究全体亦会议：泌尿生殖器官肺炎便是-乳癌、睾丸乳癌和乳癌著者简介：Liaoyuan Li等概要：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时性早期宫颈乳癌并发疗程后的基本功能疗程全体亦会议: 医学肺炎著者简介： 李珉珉等概要：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗甲状腺髓性乳癌的相关性：基于ALTER01031次测试的系统性。亦会话：头颈部著者：天津市人民政府疗养院高明博士概要：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、不等和成年对安洛替尼放射治疗后患儿命运的不良影响: ALTER01031的亚组系统性全体亦会议：头颈部著者：天津市人民政府疗养院高明博士概要：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA系统性预报I-IIIA期非小巨噬细胞肺炎（NSCLC）患儿术后入院: GASTO1035和GASTO1018的结果全体亦会议：肺炎-非小巨噬细胞暂时性-范围性/小巨噬细胞/小巨噬细胞/其他胸科肺炎著者：Si-Yu Wang等概要：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肺炎（NSCLC）里EGFR半胱氨酸磷酸化酶抑制剂的从新型耐药必要全体亦会议:肺炎-非小巨噬细胞结核肺炎著者简介：赵昕，金恰巧，满宇，欧西厢记，才与，薛武，杨少，范敏 赵昕、金恰巧、满宇、欧西厢记、才与、薛武、杨绍、范敏概要：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试里早期黑色素瘤总肉食动物的替代终点全体亦会议：黑色素瘤/皮肤乳癌著者：聂润聪，袁书爆冷，李元芳，陈英波，周志伟 聂润聪、袁书爆冷、李元芳、陈英波、周志伟概要：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗入院或结核原发性恶性骨患儿的II期学术研究全体亦会议： 肉瘤著者：唐丽娜，牛晓辉，王为震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王为振、蔡启庆、涂崇奇、范正福、杨瑶概要：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步口碑安罗替尼在早期肉瘤患儿多线放射治疗里的相容性和。全体亦会议：肉瘤著者：姚伟涛，王为家爆冷，张瑞，王为欣，杜从新辉，田志浩，牛晓颖 姚伟涛、王为家爆冷、张瑞、王为鑫、杜鑫辉、田志超、牛晓英概要：11526贴纸：414